These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

387 related items for PubMed ID: 12615720

  • 1. CD4+ T lymphocytes play a critical role in antibody production and tumor immunity against simian virus 40 large tumor antigen.
    Kennedy RC, Shearer MH, Watts AM, Bright RK.
    Cancer Res; 2003 Mar 01; 63(5):1040-5. PubMed ID: 12615720
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells.
    Utermöhlen O, Schulze-Garg C, Warnecke G, Gugel R, Löhler J, Deppert W.
    J Virol; 2001 Nov 01; 75(22):10593-602. PubMed ID: 11602701
    [Abstract] [Full Text] [Related]

  • 4. Protective immunity in BALB/c mice against the simian virus 40-induced mKSA tumor resulting from injection of recombinant large T antigen. Requirement of CD8+ T lymphocytes.
    Zerrahn J, Utermöhlen O, Warnecke G, Deppert W, Lehmann-Grube F.
    J Immunol; 1996 May 15; 156(10):3919-24. PubMed ID: 8621931
    [Abstract] [Full Text] [Related]

  • 5. Immunization of BALB/c mice with recombinant simian virus 40 large tumor antigen induces antibody-dependent cell-mediated cytotoxicity against simian virus 40-transformed cells. An antibody-based mechanism for tumor immunity.
    Bright RK, Shearer MH, Kennedy RC.
    J Immunol; 1994 Sep 01; 153(5):2064-71. PubMed ID: 8051411
    [Abstract] [Full Text] [Related]

  • 6. Comparison of humoral immune responses and tumor immunity in mice immunized with recombinant SV40 large tumor antigen and a monoclonal anti-idiotype.
    Shearer MH, Bright RK, Kennedy RC.
    Cancer Res; 1993 Dec 01; 53(23):5734-9. PubMed ID: 7694794
    [Abstract] [Full Text] [Related]

  • 7. Role of a subdominant H-2Kd-restricted SV40 tumor antigen cytotoxic T lymphocyte epitope in tumor rejection.
    Newmaster RS, Mylin LM, Fu TM, Tevethia SS.
    Virology; 1998 May 10; 244(2):427-41. PubMed ID: 9601511
    [Abstract] [Full Text] [Related]

  • 8. Tumor immunity against a simian virus 40 oncoprotein requires CD8+ T lymphocytes in the effector immune phase.
    Lowe DB, Shearer MH, Jumper CA, Bright RK, Kennedy RC.
    J Virol; 2010 Jan 10; 84(2):883-93. PubMed ID: 19889780
    [Abstract] [Full Text] [Related]

  • 9. Immunotherapy of SV40 induced tumours in mice: a model for vaccine development.
    Bright RK, Shearer MH, Pass HI, Kennedy RC.
    Dev Biol Stand; 1998 Jan 10; 94():341-53. PubMed ID: 9776255
    [Abstract] [Full Text] [Related]

  • 10. Immunization with soluble simian virus 40 large T antigen induces a specific response of CD3+ CD4- CD8+ cytotoxic T lymphocytes in mice.
    Schirmbeck R, Zerrahn J, Kuhröber A, Kury E, Deppert W, Reimann J.
    Eur J Immunol; 1992 Mar 10; 22(3):759-66. PubMed ID: 1312473
    [Abstract] [Full Text] [Related]

  • 11. Protection against a lethal challenge with SV40-transformed cells by the direct injection of DNA-encoding SV40 large tumor antigen.
    Bright RK, Beames B, Shearer MH, Kennedy RC.
    Cancer Res; 1996 Mar 01; 56(5):1126-30. PubMed ID: 8640771
    [Abstract] [Full Text] [Related]

  • 12. Immunization with adenoviral vectors carrying recombinant IL-12 and E7 enhanced the antitumor immunity to human papillomavirus 16-associated tumor.
    Jin HS, Park EK, Lee JM, NamKoong SE, Kim DG, Lee YJ, Jun HJ, Han BD, Bae SM, Ahn WS.
    Gynecol Oncol; 2005 May 01; 97(2):559-67. PubMed ID: 15863160
    [Abstract] [Full Text] [Related]

  • 13. CD4+ T cells are able to promote tumor growth through inhibition of tumor-specific CD8+ T-cell responses in tumor-bearing hosts.
    den Boer AT, van Mierlo GJ, Fransen MF, Melief CJ, Offringa R, Toes RE.
    Cancer Res; 2005 Aug 01; 65(15):6984-9. PubMed ID: 16061684
    [Abstract] [Full Text] [Related]

  • 14. Adoptive transfer enables tumor rejection targeted against a self-antigen without the induction of autoimmunity.
    Eck SC, Turka LA.
    Cancer Res; 2001 Apr 01; 61(7):3077-83. PubMed ID: 11306490
    [Abstract] [Full Text] [Related]

  • 15. Essential role of MHC II-independent CD4+ T cells, IL-4 and STAT6 in contact hypersensitivity induced by fluorescein isothiocyanate in the mouse.
    Takeshita K, Yamasaki T, Akira S, Gantner F, Bacon KB.
    Int Immunol; 2004 May 01; 16(5):685-95. PubMed ID: 15096484
    [Abstract] [Full Text] [Related]

  • 16. CD4+ T lymphocytes are critical mediators of tumor immunity to simian virus 40 large tumor antigen induced by vaccination with plasmid DNA.
    Aldrich JF, Lowe DB, Shearer MH, Winn RE, Jumper CA, Bright RK, Kennedy RC.
    J Virol; 2011 Jul 01; 85(14):7216-24. PubMed ID: 21593176
    [Abstract] [Full Text] [Related]

  • 17. Induction of potent and long-lasting CD4 and CD8 T-cell responses against hepatitis C virus by immunization with viral antigens plus poly(I:C) and anti-CD40.
    Zabaleta A, Arribillaga L, Llopiz D, Dotor J, Lasarte JJ, Prieto J, Borrás-Cuesta F, Esteban JI, Quer J, Vayreda F, Sarobe P.
    Antiviral Res; 2007 Apr 01; 74(1):25-35. PubMed ID: 17275104
    [Abstract] [Full Text] [Related]

  • 18. Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes.
    Ganss R, Hanahan D.
    Cancer Res; 1998 Oct 15; 58(20):4673-81. PubMed ID: 9788621
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.